NCT03076957View on ClinicalTrials.gov

A Phase 1/2a Study to Assess the Safety and Efficacy of CKD-516 Tab. in Combination With Irinotecan Inj.

PHASE1/PHASE2UnknownINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

December 31, 2016

Primary Completion Date

June 30, 2018

Study Completion Date

June 30, 2019

Conditions
Colorectal Cancer
Interventions
DRUG

CKD-516 Tablet

CKD-516 PO for 5 consecutive days and 2 days off in Combination with Irinotecan inj.

Trial Locations (1)

Unknown

RECRUITING

Asan Medical Center, Seoul

Sponsors

Collaborators (1)

Asan Medical Center
All Listed Sponsors
collaborator

Asan Medical Center

OTHER

lead

Chong Kun Dang Pharmaceutical

INDUSTRY

NCT03076957 - A Phase 1/2a Study to Assess the Safety and Efficacy of CKD-516 Tab. in Combination With Irinotecan Inj. | Biotech Hunter | Biotech Hunter